QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:AVTE

Aerovate Therapeutics Stock Forecast, Price & News

Notice: Trading of Aerovate Therapeutics halted at 09:32 AM EST due to "LULD pause".
$16.89
+2.76 (+19.53 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.04
$21.80
50-Day Range
$11.76
$22.49
52-Week Range
$11.40
$29.43
Volume2.22 million shs
Average Volume141,159 shs
Market Capitalization$412.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVTE News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Aerovate Therapeutics

Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTE
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$412.28 million
Next Earnings Date
11/15/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

411th out of 1,361 stocks

Pharmaceutical Preparations Industry

186th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Aerovate Therapeutics (NASDAQ:AVTE) Frequently Asked Questions

Is Aerovate Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aerovate Therapeutics stock.
View analyst ratings for Aerovate Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aerovate Therapeutics?

Wall Street analysts have given Aerovate Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aerovate Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aerovate Therapeutics?

Aerovate Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 1,110,000 shares, an increase of 30.7% from the September 15th total of 849,100 shares. Based on an average daily trading volume, of 115,400 shares, the days-to-cover ratio is currently 9.6 days. Approximately 6.5% of the company's stock are short sold.
View Aerovate Therapeutics' Short Interest
.

When is Aerovate Therapeutics' next earnings date?

Aerovate Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Aerovate Therapeutics
.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its quarterly earnings data on Sunday, August, 15th. The company reported ($23.80) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $23.64.
View Aerovate Therapeutics' earnings history
.

What price target have analysts set for AVTE?

4 brokers have issued 12-month price targets for Aerovate Therapeutics' shares. Their forecasts range from $21.00 to $23.00. On average, they anticipate Aerovate Therapeutics' share price to reach $22.00 in the next year. This suggests a possible upside of 30.3% from the stock's current price.
View analysts' price targets for Aerovate Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Aerovate Therapeutics IPO?

(AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share.

What is Aerovate Therapeutics' stock symbol?

Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE."

When does the company's lock-up period expire?

Aerovate Therapeutics' lock-up period expires on Monday, December 27th. Aerovate Therapeutics had issued 8,682,142 shares in its IPO on June 30th. The total size of the offering was $121,549,988 based on an initial share price of $14.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerovate Therapeutics' stock price today?

One share of AVTE stock can currently be purchased for approximately $16.89.

How much money does Aerovate Therapeutics make?

Aerovate Therapeutics has a market capitalization of $412.28 million.

How many employees does Aerovate Therapeutics have?

Aerovate Therapeutics employs 2,021 workers across the globe.

What is Aerovate Therapeutics' official website?

The official website for Aerovate Therapeutics is aerovatetx.com.

How can I contact Aerovate Therapeutics?

The company can be reached via phone at 617-443-2400 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.